Evidence map›Paper›PMID 40378095›Full record

ArticleThe journals of gerontology. Series A, Biological sciences and medical sciences2025

Relationship of Alzheimer's Disease and Related Dementias Plasma Biomarkers With Mobility in Cognitively Unimpaired Older Adults.

Atalie C Thompson, Xiaoyan Leng, Michael E Miller, Thomas C Register, Paul J Laurienti, Michelle M Mielke, Suzanne Craft, Stephen B Kritchevsky

Abstract read
In one paragraph

Article in The journals of gerontology. Series A, Biological sciences and medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Motor performance and its association with Alzheimer's-related biomarkers: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Atalie C ThompsonDepartment of Ophthalmology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0002-2817-6417
Xiaoyan LengDepartment of Biostatistics and Data Science, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Michael E MillerDivision of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Thomas C RegisterDepartment of Pathology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Paul J LaurientiDepartment of Radiology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Michelle M MielkeDivision of Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0001-7177-1185
Suzanne CraftDivision of Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.
Stephen B KritchevskyDivision of Gerontology and Geriatric Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.ORCID 0000-0003-3336-6781

Funding

Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI STEPHEN B. KRITCHEVSKY · 2002 to 2026
$36.4M
Wake Forest Clinical and Translational Science AwardUL1TR001420 · NCATS · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI ARD, JAMY D, FOLEY, KRISTIE L · 2015 to 2023
$32.3M
Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Combining assessment of cognition, eye movement, and gait in naturalistic settings to differentiate subclinical Alzheimer's pathology.R01AG052419 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KRITCHEVSKY, STEPHEN B., LAURIENTI, PAUL · 2017 to 2022
$4.2M
National Institute of Aging 3R01AG052419-02S1National Institute of Aging R01AG052419NCATS NIH HHS UL1 TR001420NIA NIH HHS P30 AG021332NIA NIH HHS P30 AG072947NIA NIH HHS R01 AG052419Wake Forest Alzheimer's Disease Research Center P30AG072947Wake Forest Claude D. Pepper Center P30AG021332Wake Forest Clinical and Translational Science Awards UL1TR001420
6 · The paper itself

Abstract

backgroundTemporal relationships between physical and cognitive decline with aging are poorly understood, and little is known about the underlying mechanisms linking these conditions. We hypothesized that plasma biomarkers of Alzheimer's disease and related dementias may be associated with mobility performance in older adults who are cognitively unimpaired.

methodsWe constructed separate linear mixed models to examine the cross-sectional associations of 5 plasma Alzheimer's disease and related dementias and aging-related biomarkers with 4 measures of mobility in a cohort of 192 cognitively unimpaired older adults. We secondarily described the association of the same biomarkers with 4 cognitive domain scores.

resultsHigher phorphorylated-tau181 was associated with worse performance on the expanded short physical performance battery, slower 4 m gait speed, and shorter balance time. Higher neurofilament light was associated with worse expanded short physical performance battery, slower 4 m gait speed, and slower 400 m gait speed in adjusted models. However, there was no association of Aβ42/Aβ40, p-tau217, or glial fibrillary acidic protein with mobility. Only p-tau217 was associated with global and processing speed cognitive domain scores in multivariable models, but not after adjusting for multiple comparisons.

conclusionsThese data suggest that p-tau181 and neurofilament light are potential markers of mobility performance in cognitively normal older adults, even when they are not associated with cognitive performance. Future studies should examine how such markers predict change over time in mobility and cognitive function and whether they may indicate pathways that could be targeted for preventive management.

Indexed as

Alzheimer DiseaseMobility LimitationAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersCognitionCross-Sectional StudiesFemaleHumansMaleNeurofilament Proteinstau ProteinsWalking SpeedAmyloid beta-PeptidesBiomarkersneurofilament protein LNeurofilament Proteinstau ProteinsAlzheimer’s diseaseFunctional performanceGait

Identifiers

PMID40378095
PMCPMC12198666

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.